| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Akane Yoshikawa, Jiang Li, Herbert Y Meltze. A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs. The pharmacogenomics journal. vol 20. issue 2. 2021-03-29. PMID:31636356. |
we first evaluated whether rs358532 and rs6449693, tag snps for rs6295, predicted response to lurasidone, using data from two clinical trials of acutely psychotic schizophrenia patients with european (eur, n = 171) or african (afr, n = 131) ancestry; we then determined if those findings could be replicated in a third trial of lurasidone of similar design. |
2021-03-29 |
2023-08-13 |
Not clear |
| Akane Yoshikawa, Jiang Li, Herbert Y Meltze. A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs. The pharmacogenomics journal. vol 20. issue 2. 2021-03-29. PMID:31636356. |
meta-analysis of five studies, including the three with lurasidone, showed that rs6295 was associated with improvement in positive (p = 0.023) and negative (p ≤ 0.0001) symptoms in eur patients with schizophrenia. |
2021-03-29 |
2023-08-13 |
Not clear |
| Monalisa Jena, Archana Mishra, Biswa Ranjan Mishra, Santanu Nath, Rituparna Mait. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial. Psychopharmacology. vol 237. issue 11. 2021-01-26. PMID:32740676. |
effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial. |
2021-01-26 |
2023-08-13 |
Not clear |
| Monalisa Jena, Archana Mishra, Biswa Ranjan Mishra, Santanu Nath, Rituparna Mait. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial. Psychopharmacology. vol 237. issue 11. 2021-01-26. PMID:32740676. |
this study was conducted to compare the effect of lurasidone and olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia. |
2021-01-26 |
2023-08-13 |
Not clear |
| Tatiana Karpouzian-Rogers, Jane Stocks, Herbert Y Meltzer, James L Reill. The effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia. Schizophrenia research. vol 215. 2021-01-18. PMID:31706786. |
the effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia. |
2021-01-18 |
2023-08-13 |
Not clear |
| Herbert Y Meltzer, Daniel B Share, Karu Jayathilake, Ronald M Salomon, Myung A Le. Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. Journal of clinical psychopharmacology. vol 40. issue 3. 2021-01-13. PMID:32332459. |
lurasidone improves psychopathology and cognition in treatment-resistant schizophrenia. |
2021-01-13 |
2023-08-13 |
Not clear |
| Afzal Javed, Holger Arthur, Logos Curtis, Lars Hansen, Sofia Papp. Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and therapy. vol 8. issue 2. 2021-01-09. PMID:31098889. |
practical guidance on the use of lurasidone for the treatment of adults with schizophrenia. |
2021-01-09 |
2023-08-13 |
Not clear |
| Afzal Javed, Holger Arthur, Logos Curtis, Lars Hansen, Sofia Papp. Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and therapy. vol 8. issue 2. 2021-01-09. PMID:31098889. |
lurasidone is an atypical antipsychotic that was approved in europe in 2014 for the treatment of schizophrenia in adults aged ≥ 18 years. |
2021-01-09 |
2023-08-13 |
Not clear |
| Afzal Javed, Holger Arthur, Logos Curtis, Lars Hansen, Sofia Papp. Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and therapy. vol 8. issue 2. 2021-01-09. PMID:31098889. |
clinical experience with lurasidone in europe is currently limited, and there is therefore a need to provide practical guidance on using lurasidone for the treatment of adults with schizophrenia. |
2021-01-09 |
2023-08-13 |
Not clear |
| Brian J Miller, Andrei Pikalov, Cynthia O Siu, Michael Tocco, Joyce Tsai, Philip D Harvey, John W Newcomer, Antony Loebe. Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Comprehensive psychiatry. vol 102. 2020-12-21. PMID:32896775. |
association of c-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. |
2020-12-21 |
2023-08-13 |
Not clear |
| Brian J Miller, Andrei Pikalov, Cynthia O Siu, Michael Tocco, Joyce Tsai, Philip D Harvey, John W Newcomer, Antony Loebe. Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Comprehensive psychiatry. vol 102. 2020-12-21. PMID:32896775. |
this post-hoc analysis based on a placebo-controlled trial investigated the effect of inflammation (indexed by crp) and metabolic risk factors on cognitive performance in patients with schizophrenia treated with lurasidone. |
2020-12-21 |
2023-08-13 |
Not clear |
| Christoph U Correll, Robert L Findling, Michael Tocco, Andrei Pikalov, Ling Deng, Robert Goldma. Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. CNS spectrums. 2020-12-09. PMID:33077012. |
safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. |
2020-12-09 |
2023-08-13 |
Not clear |
| Christoph U Correll, Robert L Findling, Michael Tocco, Andrei Pikalov, Ling Deng, Robert Goldma. Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. CNS spectrums. 2020-12-09. PMID:33077012. |
this study evaluated the long-term safety, tolerability, and effectiveness of lurasidone in adolescents with schizophrenia. |
2020-12-09 |
2023-08-13 |
Not clear |
| Umberto Restelli, Manuel García-Goñi, Michal Lew-Starowicz, Pawel Mierzejewski, Sofia Silvola, Jacqueline Mayoral-van Son, Davide Croce, Paola Rocca, Benedicto Crespo-Facorr. Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR. Clinical drug investigation. vol 40. issue 9. 2020-11-11. PMID:32648201. |
cost of relapse management in patients with schizophrenia in italy and spain: comparison between lurasidone and quetiapine xr. |
2020-11-11 |
2023-08-13 |
Not clear |
| Umberto Restelli, Manuel García-Goñi, Michal Lew-Starowicz, Pawel Mierzejewski, Sofia Silvola, Jacqueline Mayoral-van Son, Davide Croce, Paola Rocca, Benedicto Crespo-Facorr. Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR. Clinical drug investigation. vol 40. issue 9. 2020-11-11. PMID:32648201. |
second-generation antipsychotics (lurasidone and quetiapine xr) are recommended as the first-line treatment for schizophrenia. |
2020-11-11 |
2023-08-13 |
Not clear |
| Umberto Restelli, Manuel García-Goñi, Michal Lew-Starowicz, Pawel Mierzejewski, Sofia Silvola, Jacqueline Mayoral-van Son, Davide Croce, Paola Rocca, Benedicto Crespo-Facorr. Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR. Clinical drug investigation. vol 40. issue 9. 2020-11-11. PMID:32648201. |
the objective of this analysis was to assess the direct medical costs related to pharmaceutical treatments and the management of relapses in patients affected with schizophrenia treated with lurasidone (74 mg) vs quetiapine xr (300 mg) assuming the italian and spanish national health service perspective. |
2020-11-11 |
2023-08-13 |
Not clear |
| Michael Tocco, John W Newcomer, Yongcai Mao, Andrei Pikalov, Antony Loebe. Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia. CNS spectrums. 2020-10-27. PMID:32921337. |
lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia. |
2020-10-27 |
2023-08-13 |
Not clear |
| Michael Tocco, John W Newcomer, Yongcai Mao, Andrei Pikalov, Antony Loebe. Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia. CNS spectrums. 2020-10-27. PMID:32921337. |
to assess the effects of treatment with lurasidone on risk for metabolic syndrome (mets) in patients with schizophrenia. |
2020-10-27 |
2023-08-13 |
Not clear |
| Teruhiko Higuchi, Jun Ishigooka, Masaomi Iyo, Katsuhiko Hag. Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. vol 12. issue 1. 2020-10-21. PMID:31837113. |
safety and effectiveness of lurasidone for the treatment of schizophrenia in asian patients: results of a 26-week open-label extension study. |
2020-10-21 |
2023-08-13 |
Not clear |
| Teruhiko Higuchi, Jun Ishigooka, Masaomi Iyo, Katsuhiko Hag. Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. vol 12. issue 1. 2020-10-21. PMID:31837113. |
this study was designed to evaluate the long-term safety and effectiveness of lurasidone in the treatment of schizophrenia among asian patients. |
2020-10-21 |
2023-08-13 |
Not clear |